US4548818A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines
Assignee: AKTEBOLAGET DRACO A Co OF SWEDEN
•
Filing: 1981-11-23
•
Granted: 1985-10-22
•
Expires: 2001-11-23
Abstract
Abstract Compounds having activity against chronic obstructive airway disease or cardiac disease, characterized by the formula ##STR1## wherein R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof.
Inventors
- 👤 Per G. Kjellin
- 👤 Carl G. A. Persson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 23:35
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/52; C07D239/54; C07D239/545; A; A61; A61P; A61P11/00; A61P11/08; A61P9/00; A61P9/04; C07D473/00; C07D473/02; C07D473/04; C07D473/06
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
79 words
A pharmaceutical preparation comprising as active ingredient an effective amount of a compound of the formula ##STR18## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl, in association with a pharmaceutically acceptable carrier for use in the treatment of chronic obstructive airway disease.
Claim 2
Dependent Claim
79 words
A pharmaceutical preparation comprising as active ingredient an effective amount of a compound of the formula ##STR18## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl, in association with a pharmaceutically acceptable carrier for use in the treatment of chronic obstructive airway disease.
Claim 3
Dependent Claim
77 words
A pharmaceutical preparation comprising as active ingredient an effective amount of a compound of the formula ##STR19## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl, in association with a pharmaceutically acceptable carrier for use in the treatment of cardiac disease.
Claim 4
Dependent Claim
77 words
A pharmaceutical preparation comprising as active ingredient an effective amount of a compound of the formula ##STR19## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl, in association with a pharmaceutically acceptable carrier for use in the treatment of cardiac disease.
Claim 5
Dependent Claim
13 words
A pharmaceutical preparation according to claim 1 or 2 in dosage unit form.
Claim 6
Dependent Claim
55 words
A pharmaceutical preparation according to claim 1 comprising as active ingredient a compound of the formula ##STR20## wherein R 1 is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl; or ##STR21## wherein R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, in association with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
55 words
A pharmaceutical preparation according to claim 2 comprising as active ingredient a compound of the formula ##STR22## wherein R 1 is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl; or ##STR23## wherein R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, in association with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
14 words
A pharmaceutical preparation according to claim 4 or 5 in a dosage unit form.
Claim 9
Independent Claim
80 words
A method for the treatment of chronic obstructive airway disease in mammals, including man, characterized in administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR24## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmentyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl.
Claim 10
Independent Claim
80 words
A method for the treatment of chronic obstructive airway disease in mammals, including man, characterized in administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR24## or a physiologically acceptable salt thereof, in which formula R 1 is n-propyl, n-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmentyl, and R 2 is hydrogen or methyl, provided that R 2 is methyl when R 1 is n-propyl, n-butyl or isobutyl.
Claim 11
Dependent Claim
66 words
A method for the treatment of chronic obstructive airway disease according to claim 7 characterized in administering to a host in need of such treatment an effective amount of a compound of the formula ##STR25## wherein R 1 is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl; or ##STR26## wherein R 1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl.
References Cited (Backward Citations)
DE1245969B
Cited
DE864868C
Cited
US2646432A
Cited
GB683523A
Cited
US2781344A
Cited
US2844576A
Cited
GB982079A
Cited
DE2323906A1
Cited
DE2713389A1
Cited
US4089959A
Cited
US4120947A
Cited
US4233303A
Cited
US4325956A
Cited
US4338319A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-10-21 | 1989-04-22 | 1989-10-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-10-21 | 1993-04-22 | 1993-10-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-10-21 | 1997-04-22 | 1997-10-22 | $7700.00 | Window Closed / Lapsed |